AT7519 Multi-CDK inhibitor is a chemical agent used in the treatment of various forms of cancer. Its chemical name is 4-(9-Isopropyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrido[4,3-d]pyrimidin-7-yl)-3,5-dimethyl-isoxazole and its molecular formula is C19H23N5O2. The product has a formula weight of 357.42 g/mol and a CAS No of 844442-38-2. This article will provide information on the various aspects of AT7519, including health benefits, potential side effects, dosing information, mechanisms of action, and safety information.
Top Ten Keywords:
- Multi-CDK Inhibitor
- Cancer Treatment
- Cell Cycle
- Protein Kinase
- Antineoplastic Agents
- Apoptosis Induction
- Cyclin-Dependent Kinases
- AT 7519
Health Benefits: AT7519 has been found to have several health benefits, including its effectiveness in treating various forms of cancer. The product has been shown to inhibit cyclin-dependent kinases (CDKs), which play a vital role in regulating cell division. Therefore, AT7519 can arrest the cell cycle and induce apoptosis, leading to the death of cancerous cells. The multi-CDK inhibitor can also inhibit other protein kinases that play a role in cancer progression.
Potential Effects: AT7519 has been shown to have various potential effects, including inducing apoptosis in cancer cells, inhibiting tumor growth, and sensitizing cancer cells to chemotherapy. The product has also demonstrated efficacy in the treatment of solid tumors, including lung, colon, and breast cancers, as well as hematological malignancies such as leukemia and lymphoma.
Product Mechanism: AT7519 works by inhibiting CDKs, which control the progression of the cell cycle. By targeting multiple CDKs, the product can inhibit cell division and induce apoptosis in cancer cells. Inhibition of CDKs can also sensitize cancer cells to chemotherapy, making them more susceptible to treatment. Furthermore, AT7519 can inhibit other protein kinases, including GSK-3β and PIM1, which play a role in cancer progression.
Safety: Studies have shown that AT7519 is generally safe to use, but like any medication, it can have side effects. The product has been shown to cause thrombocytopenia, anemia, and neutropenia, which can lead to an increased risk of infection or bleeding. It can also cause gastrointestinal toxicities, such as nausea, vomiting, diarrhea, and abdominal pain. Cardiovascular toxicities, including QTc prolongation and arrhythmias, have also been reported as side effects of AT7519.
Side Effects: The most common side effects of AT7519 include gastrointestinal toxicities, such as nausea, vomiting, diarrhea, and abdominal pain. Cardiovascular toxicities, including QTc prolongation and arrhythmias, have also been reported as side effects of AT7519. The product has also been shown to cause thrombocytopenia, anemia, and neutropenia, which can lead to an increased risk of infection or bleeding. Therefore, regular monitoring of blood counts is essential when using AT7519.
Dosing Information: The dosing information for AT7519 varies depending on the indication and the stage of cancer. In clinical studies, the product has been administered at doses ranging from 50mg/m² to 400mg/m². The dosing regimen may also vary depending on the route of administration, as AT7519 can be administered orally or intravenously. Patients should always follow their healthcare provider's dosing instructions.
Conclusion: AT7519 Multi-CDK inhibitor is a promising agent for the treatment of various forms of cancer. The product works by inhibiting CDKs, which play a vital role in regulating cell division. By arresting the cell cycle and inducing apoptosis, AT7519 can effectively target cancer cells and inhibit tumor growth. While the product is generally safe to use, it can have potentially severe side effects, including thrombocytopenia, anemia, neutropenia, and gastrointestinal and cardiovascular toxicities. Therefore, it is essential to carefully monitor patients receiving AT7519 for any potential adverse effects